During the Multiple Myeloma Hub Steering Committee Meeting on May 12, 2026, key opinion leaders met to discuss strategies for managing belantamab mafodotin-associated ocular toxicities in patients with multiple myeloma (MM). The meeting featured a presentation by guest speaker Lisa Leypoldt, University Medical Center Hamburg-Eppendorf, followed by a faculty discussion on the practical challenges of monitoring, managing, and counseling patients receiving belantamab mafodotin-based therapies.
During their presentation, Leypoldt reviewed the mechanisms underlying belantamab mafodotin-associated ocular toxicity, highlighting the role of off-target uptake into corneal epithelial cells and the resulting transient visual symptoms. Leypoldt discussed the clinical manifestations of ocular events, including keratopathy, changes in visual acuity, and patient-reported symptoms, before outlining evidence-based approaches to monitoring and management. Leypoldt also reviewed data from the DREAMM-7 (NCT04246047) and DREAMM-8 (NCT04484623) studies, evaluating the role of dose modifications and extended dosing intervals in managing ocular toxicity. The subsequent faculty discussion focused on multidisciplinary care, patient counseling, and practical considerations for integrating ocular toxicity monitoring into routine clinical practice.
This educational resource is independently supported by GSK. All content is developed by the faculty in collaboration with SES. Funders are allowed no influence.
","author_name":"Scientific Education Support"}